GlobeNewswire

SD-WAN Market Leader Aryaka Selected Among Finalists for Marketers That Matter® Award for Tripling Revenue in Last Three Years

Dela

Marketing leadership honored among top brands such as Autodesk, Intel, Nest, PepsiCo, Old Navy, Samsung Electronics, and YouTube

SAN MATEO, Calif., May  03, 2018  (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, announced today that its marketing organization has been recognized as a 2018 Marketers That Matter® Finalist in the "Driving Growth" and "Transformation Journey" categories. Through tripling revenue and improving its brand recognition score by 32 times in the last three years, Aryaka represents the first SD-WAN provider included on the list of finalists.

Over the past three years Aryaka has expanded its customer base to more than 800 global enterprises. It is now the number one pure play provider in the SD-WAN category by market share and revenue.

"By listening to our customers and maintaining a relentless dedication to their business success, we have effectively shifted how we attract and retain them. In 2015, most of our demand came from outbound activities. Today, the majority of direct sales comes from inbound requests," said Gary Sevounts, Chief Marketing Officer at Aryaka. "We leveraged data science and took a 360° approach to refine our marketing mix, content, and message to best resonate with customer needs."

Sponsored by The Wall Street Journal, the Marketers That Matter® Awards recognize innovative marketing initiatives that are creating measurable results. Executives will gather on May 17th for the MTM Gala to honor the finalists and announce the winners. An elite panel of judges comprised of CEOs, CMOs, and senior executives from Clif Bar, Facebook, Google, LinkedIn, Logitech, Old Navy, OpenTable, Salesforce, Sephora, Visa and many others select the finalists and winners based on their creative approach, company impact, and measurable results.

"The best marketers today are focused on new approaches that drive business results for their companies and the customers they serve," said Cara France, Sage Group CEO. "The Marketers that Matter Finalists are mastering marketing in this transformative time."

"This recognition reaffirms our marketing organization's dedication and hard work, enabling us to maintain a 70 - 100% year-over-year growth rate and a 98% customer retention rate," said Shawn Farshchi, President and CEO of Aryaka.

Last week, Aryaka announced that it was named among "Hottest Privately Held Companies" in the JMP Securities' Super 70 list of the fastest-growing cybersecurity, data management and communications infrastructure companies. Recently, Aryaka also won the "2018 SD-WAN Leadership Award" from TMC and was named a market leader in the "FeaturedCustomers' 2018 SD-WAN Customer Success Report."

For more information about Aryaka's award-winning global SD-WAN, visit www.aryaka.com.

About Aryaka Networks
Aryaka is transforming how global enterprises connect sites and users worldwide, and use mission-critical applications to support modern business execution demands. Aryaka's Global SD-WAN combines a purpose-built private network, SD-WAN, optimization and acceleration techniques, connectivity to cloud platforms, and network visibility in a single solution that is delivered as a service.

To learn more, visit www.aryaka.com. Follow us on Twitter,  FacebookYouTube  and LinkedIn.

About Marketers that Matter®
Marketers that Matter (MTM) is the leading community of top marketing executives and companies coming together to drive marketing innovation and business results.  Members benefit from exclusive events, compelling learnings, and opportunities to showcase their brands.  Now in its sixth year, the MTM Awards recognize marketing teams for innovative programs with measurable impact.  Visit www.marketersthatmatter.com .

Aryaka Media Contact
Shehzad Karkhanawala
Director of Marketing
Aryaka
408-273-8420
pr@aryaka.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aryaka via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum